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Hepáticas y Digestivas (CIBERehd), San Sebastián, Spain, 2 Department of Epidemiology, CIBERESP, Donostia Hospital, San Sebastián, Spain, 3 Department of Surgery,
Donostia Hospital, San Sebastián, Spain, 4 Department of Gastroenterology, Clinic Hospital, CIBERehd, IDIBAPS, Barcelona, Spain
Abstract
Background: Colorectal cancer (CRC) is the second most common cause of death from cancer in both men and women in
the majority of developed countries. Molecular tests of blood could potentially provide this ideal screening tool.
Aim: Our objective was to assess the usefulness of serum markers and mRNA expression levels in the diagnosis of CRC.
Methods: In a prospective study, we measured mRNA expression levels of 13 markers (carbonic anhydrase, guanylyl cyclase
C, plasminogen activator inhibitor, matrix metalloproteinase 7 (MMP7), urokinase-type plasminogen activator receptor
(uPAR), urokinase-type plasminogen activator, survivin, tetranectin, vascular endothelial growth factor (VEGF), cytokeratin
20, thymidylate synthase, cyclooxygenase 2 (COX-2), and CD44) and three proteins in serum (alpha 1 antitrypsin,
carcinoembryonic antigen (CEA) and activated C3 in 42 patients with CRC and 33 with normal colonoscopy results.
Results: Alpha 1-antitrypsin was the serum marker that was most useful for CRC diagnosis (1.7960.25 in the CRC group vs
1.2760.25 in the control group, P,0.0005). The area under the ROC curve for alpha 1-antitrypsin was 0.88 (0.79–0.96). The
mRNA expression levels of five markers were statistically different between CRC cases and controls: those for which the ROC
area was over 75% were MMP7 (0.81) and tetranectin (0.80), COX-2 (0.78), uPAR (0.78) and carbonic anhydrase (0.77). The
markers which identified early stage CRC (Stages I and II) were alpha 1-antitrypsin, uPAR, COX-2 and MMP7.
Conclusions: Serum alpha 1-antitrypsin and the levels of mRNA expression of MMP7, COX-2 and uPAR have good diagnostic
accuracy for CRC, even in the early stages.
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Introduction
Colorectal cancer (CRC) is a major cause of morbidity and
mortality worldwide and is the second most common cause of
cancer death in Europe and the United States [1,2]. The overall
five-year survival rate is less than 65% and when the cancer is
already at an advanced stage when diagnosed treatment has very
limited success. Currently, 25% of patients have metastasis at the
time of diagnosis [3]. Detection of cancer at early stages is critical
for curative treatment interventions. However, the invasive,
unpleasant and inconvenient nature of current diagnostic proce-
dures limits their applicability. Noninvasive molecular approaches
would enable detection of relevant lesions at the population level
and could be enhanced by widely distributable screening tools that
are accurate, user-friendly, safe and affordable. Nonconventional
methods could potentially meet all of the desired criteria of an
ideal screening tool, so there is good reason to pursue rationally
designed alternative approaches.
In particular, molecular tests of blood could potentially provide
this ideal screening tool. However, the use of single or a
combination of serum markers, including carcinoembryonic
antigen (CEA), has so far failed to deliver diagnostic tests of high
sensitivity and specificity for CRC.
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There is reasonable hope and further evidence emerging that
the presence of CRC could be detected by specific changes in the
composition of serum proteins or mRNA expression levels [4].
Different markers are overexpressed in CRC compared with
matched normal adjacent mucosa [5]. These observations suggest
a model wherein as a key regulator of epithelial cell proliferation
along the associated with neoplastic transformation. The targeting
of RNA makes use of the fact that tumour phenotypic variation is
associated with changes in the mRNA levels of genes regulating or
effecting this variation. This has led to the widespread use of real-
time reverse transcription polymerase chain reaction (RT-PCR)
assays for the study of tumour dissemination as well as many
reports describing its use in clinical diagnostics [6]. In addition, the
levels of mRNA expression in blood for various proteins, in
particular cyclooxygenase 2 (COX-2), vascular endothelial growth
factor (VEGF) and others including metalloproteinase [7–9], have
been proposed for CRC diagnosis and prognosis. Various different
serum markers such as the complement protein C3a and alpha 1-
antitrypsin have been judged to be useful in the diagnosis of CRC
[10,11]. Some of them, such as VEGF or urokinase-type
plasminogen activator receptor (uPAR) have been studied in
other intestinal diseases such as inflammatory bowel disease and
have not found elevated [12,13]. Other markers, such as
tetranectin were found elevated in other gastrointestinal and
gynecological tumors [14,15].
Our objective in this study was to assess the usefulness of
different serum and mRNA expression markers for the diagnosis of
CRC.
Materials and Methods
Sixteen serum markers were studied prospectively in 42 patients
with CRC and 33 healthy controls. Individuals with CRC who
had inflammatory bowel disease and polyps were excluded.
Participants with CRC were staged according to the 5th edition
of the TNM classification [16].
The controls were individuals with no signs or symptoms of
chronic disease and who had undergone a colonoscopy to the
caecum with normal results. These controls were not taking drugs
or NSAIDs. For all participants the following data was collected:
age, weight, height, body mass index (BMI), associated medical
conditions and medications taken.
The serum markers measured were alpha 1-antitrypsin,
complement protein C3a and CEA. The markers in the blood
analysed by RNA extraction, cDNA synthesis and quantitative
PCR (qPCR) were carbonic anhydrase, guanylyl cyclase C,
plasminogen activator inhibitor (PAI), matrix metalloproteinase
7 (MMP7), uPAR, urokinase-type plasminogen activator (uPA),
survivin, tetranectin, VEGF, cytokeratin 20, thymidylate synthase,
COX-2 and CD44. These last markers were determined in
tumoral tissue and healthy tissue obtained after surgical resection
of CRC. All markers were selected based on their relationship to
diagnosis or prognosis in CRC after a review of the literature
(Table S1).
For each participant, two fasting blood samples were taken from
the antecubital vein. These blood tests were carried out in the 24
hours prior to surgery in the case of the patients diagnosed with
CRC and 24 hours following the colonoscopy in the controls.
One of these samples was used to determine three proteins in
serum (alpha 1-antitrypsin, activated C3 and CEA levels), while
mRNA was extracted from the other. Blood samples from all
participants were collected in PAXgene RNA blood tubes
(QIAGEN, K2E 18.0 mg – BD, Plymouth, UK) and kept frozen
at 280uC until RNA extractions were carried out.
Measurement of Alpha 1-antitrypsin, Activated C3 and
CEA Levels
The level of CEA in the serum was determined using an
electrochemiluminescence immunoassay. Pre-operative levels of
serum CEA of #5.0 ng/mL were considered normal.
Measurements of the serum concentration of complement C3a
were performed using the OptEIA Human C3a ELISA kit (BD
Biosciences Pharmingen, San Diego, CA, USA). Normal levels for
serum complement C3a was taken to be between 10 mg/dl and
40 mg/dl.
Alpha 1-antitrypsin (g/l) concentrations were determined using
an enzyme immunoassay kit (Dade Behring, Newark, NJ, USA) on
a BN II ProSpec nephelometer. A cut-off level of 1.5 g/L was
chosen as the upper limit of normal.
RNA Extraction and cDNA Synthesis
Total RNA from 2.5 ml whole blood collected in the PAXgene
blood RNA tubes was extracted using PAXgene Blood Minikit
(QIAGEN, PreAnalytix cat: 762164) according to manufacturer’s
instructions. Each RNA sample was quantified and quality
assessed using an Agilent 2100 bioanalyzer system to obtain an
RIN value. The RIN algorithm allows RNA integrity to be
calculated using a trained artificial neural network based on the
determination of the most informative features that can be
extracted from the electrophoretic traces out of 100 features
identified through signal analysis {IMBEAUD, 2005 #42}.
Total RNA from 20–30 mg of tissue (tumoral and healthy) was
extracted using the RNeasy Plus Mini Kit (QIAGEN) following
manufacturers instructions. This kit includes a DNase step which
removes contaminant genomic material from RNA extractions.
Using mg of RNA.
cDNA was synthesized by reverse transcription using a
Superscript III kit (Invitrogen Ltd., Paisley, UK) following
manufacturer’s instructions in a total volume of 20 ml. Subse-
quently cDNA was prepared from 1 mg of RNA using the
Superscript III RT PCR kit (Invitrogen).
Quantitative PCR (qPCR)
The qPCR was performed using a Bio-Rad iQ5 system with a
total of 13 CRC potential markers (Table 1). Each qPCR reaction
contained a gene-specific oligonucleotide primer set (25 uM),
12.5 ml Platinum qPCR supermix (Invitrogen) and 1/20 of the
original cDNA reaction mix. Each reaction was carried out in
duplicate, together with a negative control (H2O as template).
PCR efficiency was assessed by performing triplicates of 5-fold
serial dilutions from a pool of cDNA derived from 12 healthy
individuals to obtain an R2 value of .0.98. To compensate for
RNA degradation and variability in the starting amounts of RNA,
four housekeeping genes, chosen with the GenEx Light Software
(TATAA Biocenter, Sweden) from a panel of 13 genes, were used
as endogenous controls (GAPDH, HPRT1, PPIA and TBP).
The amplification values obtained from each of the 13 markers
used in this analysis were divided by the corresponding
amplification values for each of the housekeeping genes to produce
an expression index. Of these, GAPDH produced the most stable
results and was used in further analysis.
To determine changes in levels of expression of all the 13
markers in relation to the housekeeping genes we used the
comparative DCT method where the copy number of the marker
gene (target) in the samples from patients with CRC (tumour) is
compared to the relative amount of the target gene in normal
cDNA from either its corresponding paired-sample or pooled
mRNA Expression for Diagnosis of Colorectal Cancer
PLOS ONE | www.plosone.org 2 January 2013 | Volume 8 | Issue 1 | e51810
blood samples and relative to expression of the housekeeping gene,
which was used as an endogenous control (reference).
All CRC markers used in this study and their corresponding
oligonucleotide primer sequences are listed in Table 1.
The committee for clinical research ethics committee of
Country Basque approved this study and all participants gave
written informed consent.
Statistical Analysis
The comparison of the parameters analysed between CRC
cases and controls were carried out using the Student’s t-test. In
addition, ROC (Receiving Operating Characteristic) curve anal-
ysis, with calculation of both the area under the curve and the
corresponding 95% confidence intervals, was used to assess the
accuracy with which the parameters diagnosed CRC, that is,
whether they could be used to discriminate between patients with
CRC and controls. To evaluate the differences in some markers
according to the stage has been applied univariate generalized
linear model which has assessed linear trend by polynomial
contrasts and multiple comparisons (post-hoc) pairwise Tukey’s
test. Analyses were performed by using the SPSS statistical
software, version 19 and MedCalc version 6.
Results
Subjects
Of the 42 patients with CRC 25 (59%) were men and 17 (41%)
women. Their mean age was 72.33 years old and their BMI was
26.57. The tumours were classed as Stage I in 8 patients (20%),
Stage II in 14 (33%), Stage III in 17 (40%) and Stage IV in 3
patients (7%).
Of the 33 controls, 20 (60%) were men and 13 (40%) were
women, their mean age being 75 years old and BMI 26. There
were no significant differences between the cases and controls in
terms of age, sex or BMI.
When serum data were analysed, there were significant
differences between cases and controls in the levels of alpha 1-
antitrypsin. The alpha 1-antitrypsin levels were 1.7960.25 in the
patients with CRC compared to 1.2760.4 in the controls
(p,0.0005). CEA in serum was 1.561 in controls and 8.5615
in cases (p = 0.01). However, differences in complement protein
C3a concentrations between cases and controls were not
significant (14.5664.08 vs 12.8966.5; p = 0.28).
mRNA expression levels of survivin, MMP7, uPA, COX-2 and
CD44 were increased statistically significant in tissue with CCR
versus normal tissue whereas carbonic anhydrase, tetranectin, and
cytokeratin 20 were significantly decreased (Table 2).
The mRNA expression levels in blood are reported in Table 3.
Among these, there were five markers in which the differences
between cases and controls were significant, namely, carbonic
anhydrase, MMP7, uPAR, tetranectin, and COX-2. There were
no significant differences in any of the 16 markers studied
according to sex.
In the case of the two serum markers that showed significant
differences, the areas under the ROC curve were 0.88 (0.7–0.9) for
alpha 1-antitrypsin and 0.84 (0.6–0.9) for CEA.
For the mRNA expression, the areas under the ROC curve for
the different markers are listed in Table 4. The highest diagnostic
accuracies were found for MMP7 (0.81) and tetranectin (0.80),
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COX-2 (0.78), uPAR (0.78) and carbonic anhydrase (0.77)
(Table 4). For screening, a context in which the priority is
sensitivity and minimisation of false negatives, a suitable cut-off
was 1.43 for alpha 1 antitrypsin, giving a sensitivity of 87% and a
specificity of 73%. A value for MMP7 of 15.4 was the cut-off that
minimised the percentage of false negatives, giving a sensitivity of
58% and specificity of 100% (Figure 1). In Figure 2 compares the
area under the ROC curve between serum CEA and mRNA
expression of MMP7.
When the values of the markers were compared between
controls and patients with Stage I or II CRC, it was observed that
alpha 1-antitrypsin, uPAR, COX-2 and MMP7 levels were
significantly different, indicating that these compounds could be
useful for the early detection of CRC (Table 5). By contrast,
differences between groups in CEA and tetranectin were only
significant for advanced tumours (Stages III and IV), indicating
that are not suitable for early diagnosis of CRC.
Discussion
CRC has several the characteristics to justify population-wide
screening: high prevalence, the occurrence of precancerous
lesions, and the existence of treatment that is effective when
applied in the early stages. The heterogeneity of colorectal
neoplasms must be taken into account in selecting markers for
molecular detection and determining the frequency of screening
tests. Detection of these markers in blood depends on a cascade of
biological events. Markers must be regularly released from
tumours or precancerous lesions, dispersed into the medium that
is collected for the assay, survive metabolic degradation, and be
measurable [4]. In our study we analyzed 16 potential blood
markers and watched as three may be useful in identifying early-
stage CRC (uPAR, MMP7, COX-2 and alfa 1 antitrypsin). The
combination of them could be useful for screening of CRC. Two
of the 3 markers are mRNA expression determined by real-time or
quantitative PCR (qPCR). This simply method is a variation of the
standard PCR technique used to quantify mRNA in a sample.
Using specific sequence primers, it is possible to determine the
number of copies or relative quantity of given sequences of RNA.
When real-time PCR is combined with reverse-transcription
(sometimes called qRT-PCR), the quantity of mRNA in a sample
can be ascertained for different proteins [6]. With this approach, it
Table 2. The levels of mRNA expression of the proteins analysed and the statistical significance of differences in the values











Carbonic anhydrase 9,02(29.5)64.3 0,35(20.9)62.5 8.61 0.000
Guanylyl cyclase C 6.90(27.4)62.5 6.61(27.2)61.1 0.15 0.06
PAI-1 10.1(28.9)62.3 11.5(31.2)62.6 2.20 0.02
MMP7 5.58(25.6)62.1 10.09(30.7)63.7 5.07 0.000
Survivin 6.21(26.2)61.1 6.88(27.1)60.7 0.8 0.03
uPAR 9.84(29.6)62.3 9.33(29.9)62.8 0.29 0.5
Tetranectin 8.68(29.8)62.9 4.78(25.8)61.3 3.96 0.000
uPA 6.34(24.4)61.3 8.58(26.1)63.6 1.72 0.005
VEGF 8.27(29.4)62.1 9.31(30.4)61.7 0.98 0.06
Cytokeratin 20 6.62(27.3)62.3 2.58(23.2)61.0 4.02 0.000
Thymidylate synthase 6.19(25.3)61.0 6.16(25.1)60.7 0.14 0.9
COX-2 7.45(26.6)61.9 8.79(27.8)61.5 1.28 0.002
CD44 12.67(32.5)62.0 14.37(33.9)61.1 1.44 0.01
SD; standard deviation PAI; plasminogen activator inhibitor MMP7;matrix metalloproteinase 7 uPAR; urokinase-type plasminogen activator receptor uPA;urokinase-type
plasminogen activator VEGF; vascular endothelial growth factor COX-2; cyclooxygenase 2.
doi:10.1371/journal.pone.0051810.t002
Table 3. The levels of mRNA expression in blood of the
proteins analysed and the statistical significance of differences






(Mean Ct) p value
Carbonic anhydrase 2.14(22.8)63.6 4.46(22.6)61.3 0.02
Guanylyl cyclase C 7.42(28.5)62.9 7.54(26.4)64.7 0.06
PAI-1 14.96(35.2)62.8 16.06(34.2)62.0 0.19
MMP7 15.51(35.2)61.6 17.46(35.2)61.3 0.001
Survivin 9.30(31.3)63.3 10.34(29.9)61.0 0.26
uPAR 8.77(30.8)62.9 6.92(25.1)60.8 0.004
Tetranectin 13.39(33.8)61.2 11.34(29.1)63.7 0.007
uPA 9.28(29.7)63.6 10.10(27.7)61.5 0.98
VEGF 9.85(30.8)64.4 10.99(28.2)61.6 0.83
Cytokeratin 20 14.08(34.4)63.3 14.55(32.7)62.2 0.6
Thymidylate synthase 8.44(28.3)61.4 8.44(26.0)61.0 0.9
COX-2 6.86(26.2)61.1 5.91(23.6)60.5 0.02
CD44 10.87(28.3)64.3 10.62(27.4)61.4 0.3
SD; standard deviation PAI; plasminogen activator inhibitor MMP7;matrix
metalloproteinase 7 uPAR; urokinase-type plasminogen activator receptor
uPA;urokinase-type plasminogen activator VEGF; vascular endothelial growth
factor COX-2; cyclooxygenase 2.
doi:10.1371/journal.pone.0051810.t003
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has been observed, for instance, that CEA mRNA expression in
blood can predict recurrence in gastric cancer [17], esophageal
squamous cell carcinoma [18] and CRC [19].
Soluble tetranectin was measured preoperatively in serum from
patients with primary colorectal cancer. Tetranectin is a recently
described human plasma protein, which is found in most secretory
cells throughout the body and has been found to be a strong
prognostic factor in patients with CRC in others studies [20].
Specifically, significant correlations were found between tetra-
nectin and Dukes’ stages and other biochemical markers, such as
PAI, uPAR and CEA. However, there are no previous reports of
studies examining the tetranectin mRNA expression for CRC
diagnosis. In our study, it was found that the expression of
tetranectin mRNA had a good sensitivity and specificity (78% and
86%, respectively) to a cutoff of 12,8.
There is considerable experimental evidence that uPAR is
functionally involved in cancer invasion, consistent with its ability
to concentrate and enhance uPAR activity on the cell surface [21].
The level of the uPAR is elevated in tumour tissue from several
forms of cancer [22]. It is known that uPAR is shed from the cell
surface and the soluble form uPAR has been detected in several
body fluids. The preoperative plasma uPAR level independently
was found to predict survival of patients with CRC. In that study,
the plasma concentration of uPAR was measured by a kinetic
ELISA method in EDTA-anticoagulated plasma and not by level
of expression of mRNA in serum as in our study. In colon cancer
uPAR mRNA expression is enhanced in tumour cells [23]. In our
study the expression on blood showed significant differences with
controls y entre controles y pacientes con estadios I-II de CCR.
Other studies have demonstrated how mRNA expression levels
of angiogenic factors, such as VEGF, in liver metastasis can be
predicted from those in primary colorectal cancer [7]. Further, the
measurement of thymidylate synthetase mRNA in primary
colorectal cancer can reflect those in synchronous liver metastases
[24]. However, most studies have investigated the levels of mRNA
expression in tissue but not in blood as we have. We did not
Figure 1. The results shown are the levels of alpha1 antitrypsin, tetranectin, COX-2 and matrix metalloproteinase 7 (MMP7) for the
healthy individuals and patients with colorectal cancer. The cutoff corresponds with highest accuracy (minimal false negative and false
positive). Shows the sensitivity and specificity for the cutoff with highest accuracy.
doi:10.1371/journal.pone.0051810.g001
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observe differences in thymidylate synthetase and VEGF in tissue
or blood of patients with CRC. Is possible that there were not
differences due to the small number of patients with stage IV.
Proteomic profiling of serum from patients with CRC and
controls combined with the use of artificial neural networks was
able to diagnose CRC with 94% sensitivity and 96% specificity in
a cohort of patients. Using surface-enhanced laser desorption/
ionisation (SELDI), Ward et al. in 2006 [25] identified four
proteins (alpha 1-antitrypsin, complement C3a, transferrin and
apolipoprotein C1) potentially useful for the diagnosis of CRC.
The proteins identified are common serum proteins and changes
in their concentrations most likely reflect epiphenomena rather
than secretion by cancer cells. In that study (24), CEA was
measured in all of the samples (62 CRC patients and 31 subjects
not diagnosed with cancer), and a using the manufacture’s
recommended cut-off level of 4 ng/ml, the sensitivity and
specificity obtained was 53% and 93%, respectively. By contrast,
in our study, though we also studied the levels of transferrin we did
not find significant differences between patients with CRC and
controls, (225.4653.69 vs 231.1637.1; p = 0.60) with an area
under the ROC curve of 0.47 (0.34 to 0.61). Levels of
apolipoprotein C1, on the other hand, were not investigated.
CEA is clinically used as marker of CRC progression, but alone is
not useful as a marker diagnostic [26]. In our study, the ROC
values was higher to others studies [27], but was not useful in
differentiating early stages and a control group. Unlike other
studies, the combination with other markers did not improve the
ROC curve.
Elevated serum alpha 1-antitrypsin levels have been observed in
association with malignancy and inflammation. Some authors
[10,26] have shown that serum alpha 1-antitrypsin levels
correlated with CRC and with clinical staging. In these studies,
the correlation of CEA and alpha 1-antitrypsin to the stage of
disease had almost the same statistical weight (p,0.004 and
p,0.003)(26). The other three markers (C-reactive protein, alpha
1-acid glycoprotein and the percentage of serum protein
electrophoretic components) in the series of Stamatiadis et al.
[26] had a less significant correlation to the spread of the disease.
Nevertheless, their potential role in the diagnosis of CRC,
Figure 2. ROC curves comparing carcinoembrionic antigen (CEA) in serum and MMP7 RNA expression. The areas under ROC curve for
CEA and matrix metalloproteinase 7 (MMP7) were 0.84 and 0.81, respectively.
doi:10.1371/journal.pone.0051810.g002
Table 4. The areas under ROC curve for all the mRNA
expression levels analysed in blood.
Area under the ROC curve
Carbonic anhydrase 0.77 (0.6–0.9)








Cytokeratin 20 0.50 (0.3–0.6)
Thymidylate synthase 0.52 (0.4–0.7)
COX-2 0.78 (0.6–0.9)
CD44 0.72 (0.6–0.8)
PAI; plasminogen activator inhibitor MMP7;matrix metalloproteinase 7 uPAR;
urokinase-type plasminogen activator receptor uPA;urokinase-type
plasminogen activator VEGF; vascular endothelial growth factor COX-2;
cyclooxygenase 2.
doi:10.1371/journal.pone.0051810.t004
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especially in comparison with other mRNA expression markers
had not been established until now. Interestingly, high levels of
alpha 1-antitrypsin in gastric juice have been associated with
gastric cancer [27,28]. In our study we observed that serum levels
of alpha 1-antitrypsin were increased compared to controls. Serum
levels were increased by stage and discriminated between early
and advanced stages.
Complement C3a is highly biologically active, binding to mast
cells and basophils and triggering the release of their vasoactive
contents. The elevated level of complement C3a in the serum of
CRC patients may reflect an immune response to the tumour, or
possibly in vitro complement activation [29]. Based on a specific
ELISA, serum levels of complement C3a predicted the presence of
CRC in a blinded validation set with a sensitivity of 96.8% and a
specificity of 96.2% [11]. Increased serum levels were also detected
in 86.1% of independently collected sera from patients with
colorectal adenomas, while only 5.6% were classified as normal. In
our study it was not useful to discriminate cases and controls.
The discrepancies observed in some markers in our study
between tissue and blood may be due to different reasons, first, not
all mRNA is overexpressed in tumor tissue enter in blood. Second,
the mRNA extracted from whole blood comes from blood cells
(leukocytes, platelets …), very different from mRNA extracted
from CCR. Third, the blood carries RNases (enzymes that
degrade RNA), so that RNA circulating in the blood is more likely
to be degraded. This is more difficult to occur in the RNA
extracted from tumor cells.
Among the limitations of the study are; first, the small sample
size; second, unknown if the results well be reproduced in
asymptomatic individuals over 50 years (screening); finally, we also
unknown whether the expression of these markers in patients with
other gastrointestinal diseases such as inflammatory bowel disease,
may be altered. Other studies are needed in other diseases and
other gastrointestinal tumors to determine the value of these
markers in these diseases. For example, tetranectin has not been
studied in inflammatory bowel disease but has been elevated in
other tumors such as gynecological, gastric, etc.
In summary, we report that alpha 1-antitrypsin and uPAR,
COX-2 and MMP7 mRNA expression in blood could be useful
for the early diagnosis and/or screening of CRC. Further studies
in other cohorts the patients and screening programs are required
involving larger numbers of subjects to confirm these results.
Supporting Information
Table S1 mRNA expression selected, samples where were




Performed the experiments: A. Cosme EH JMEN CP EV MHV.
Contributed reagents/materials/analysis tools: A. Cosme EH JMEN CP
EV MHV. Wrote the paper: LB MG CS. A qui ed, analyzed and
interpreted the data: CS LB MG MHV EH MDG FB A. Castells.
Critically revised the manuscript for important intellectual content: LB.
References
1. La situación del cáncer en España. Spanish Ministry of Health and Consumer
Affairs. Madrid. 2005.
2. Greenlee R, Hill-Harmon MB, Murria T, Thun M (2001) Cancer statistics.
Cancer J Clinic 51: 15–36.
3. Bujanda L, Sarasqueta C, Hijona E, Hijona L, Cosme A, et al. (2010) Colorectal
cancer prognosis twenty years later. World J Gastroenterol. 16: 862–867.
4. Ahlquist DA (2010) Molecular detection of colorectal neoplasia. Gastroenteroloy
138: 2127–2129.
5. Birbe R, Palazzo JP, Walters R, Weinberg D, Schulz S, et al. (2005) Guanylyl
cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of
the gastrointestinal tract. Hum Pathol 36: 170–179.
6. Bustin SA, Mueller R (2006) Real-time transcription PCR and the detection of
occult disease in colorectal cancer. Mol Aspects Med 27: 192–223.
7. Kobayashi H, Sugihara K, Uetake H, Higuchi T, Yasuno M, Enomoto M, et al.
Messenger RNA expression of COX-2 and angiogenic factors in primary
colorectal cancer and corresponding liver metastasis. Int J Oncol 2009;34: 1147–
53.
8. Hurst NG, Stocken DD, Wilson S, Keh C, Wakelam MJ, et al. (2007) Elevated
serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence
of colorectal neoplasia in symptomatic patients. Br J Cancer 97: 971–977.
9. Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjänen S, et al. (2008) VEGF-
1 expression in colorectal cancer is associated with disease localization, stage,
and long-term disease-specific survival. Anticancer Res 28: 3865–3867.
10. Bernacka K, Kurryliszyn-Moskal A, Sierakowski S (1988) The levels of alpha 1-
antitrypsin and alpha 1-antichymotrypsin in the sera of patients with
gastrointestinal cancer during diagnosis. Cancer 62: 1188–1193.
11. Habermann JK, Roblick UJ, Luke BT, Prieto DA, Finlay WJJ, et al. (2006)
Increased serum levels of complement C3a anaphylatoxin indicate the presence
of colorectal tumors. Gastroenterology 131: 1020–1029.
Table 5. The mean levels of serum markers and mRNA expression in blood in the control group, patients with early stage (Stages I









Mean±SD A vs B A vs C
p value
(Linear trendline)
Alpha1-antitrypsin 1.3±0.3 1.8±0.3 1.7±0.5 ,0.0005 ,0.0005 ,0.0005
CEA 1.6±1.0 6.4±10.6 9.8±19.2 NS 0.04 0.01
Complement C3a 12.9±4.1 15.7±6.5 13.2±6.6 NS NS NS
MMP7 17.5±1.3 15.5±1.8 15.4±1.6 0.01 0.02 0.005
uPAR 6.9±0.8 10.1±3.0 7.7±2.8 0.003 NS NS
Tetranectin 11.361.2 12.961.2 13.761.3 NS 0.04 0.01
COX-2 5.960.5 7.061.4 6.860.9 0.03 NS 0.02
CD44 10.661.4 11.464.5 10.464.2 NS NS NS
NS; Not significant SD; standard deviation uPAR; urokinase-type plasminogen activator receptor VEGF; vascular endothelial growth factor.
COX-2; cyclooxygenase 2 CEA; carcinoembryonic antigen MMP7;matrix metalloproteinase 7.
doi:10.1371/journal.pone.0051810.t005
mRNA Expression for Diagnosis of Colorectal Cancer
PLOS ONE | www.plosone.org 7 January 2013 | Volume 8 | Issue 1 | e51810
c r
12. Sivridis E, Koukourakis MI (2003) Vascular endothelial growth factor in
inflammatory bowel disease. Int J Colorectal Dis 18: 418–422.
13. Grabarczyk E, Szaflarska-Popławska A, Góralczyk K, Adamska I, Rość D (2007)
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